Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT001 in Ischemic Stroke in the Sequelae Stage
NCT07841496Phase 2Not yet recruiting
- Sponsor
- Darwin Biotechnology
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ALT001 in ischemic stroke, sponsored by Darwin Biotechnology. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ALT001
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07841496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841496.